Cargando…
Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast cancer survivors as a consequence of the axillary lymphatics' impairment after therapy (mainly axillary surgery and irradiation). Despite the recent achievements in the clinical management of these patients, BCRL i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142240/ https://www.ncbi.nlm.nih.gov/pubmed/32300557 http://dx.doi.org/10.3389/fonc.2020.00422 |
_version_ | 1783519337317924864 |
---|---|
author | Invernizzi, Marco Lopez, Gianluca Michelotti, Anna Venetis, Konstantinos Sajjadi, Elham De Mattos-Arruda, Leticia Ghidini, Michele Runza, Letterio de Sire, Alessandro Boldorini, Renzo Fusco, Nicola |
author_facet | Invernizzi, Marco Lopez, Gianluca Michelotti, Anna Venetis, Konstantinos Sajjadi, Elham De Mattos-Arruda, Leticia Ghidini, Michele Runza, Letterio de Sire, Alessandro Boldorini, Renzo Fusco, Nicola |
author_sort | Invernizzi, Marco |
collection | PubMed |
description | Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast cancer survivors as a consequence of the axillary lymphatics' impairment after therapy (mainly axillary surgery and irradiation). Despite the recent achievements in the clinical management of these patients, BCRL is often diagnosed at its occurrence. In most cases, it remains a progressive and irreversible condition, with dramatic consequences in terms of quality of life and on sanitary costs. There are still no validated pre-surgical strategies to identify individuals that harbor an increased risk of BCRL. However, clinical, therapeutic, and tumor-specific traits are recurrent in these patients. Over the past few years, many studies have unraveled the complexity of the molecular and transcriptional events leading to the lymphatic system ontogenesis. Additionally, molecular insights are coming from the study of the germline alterations involved at variable levels in BCRL models. Regrettably, there is a substantial lack of predictive biomarkers for BCRL, given that our knowledge of its molecular milieu remains extremely puzzled. The purposes of this review were (i) to outline the biology underpinning the ontogenesis of the lymphatic system; (ii) to assess the current state of knowledge of the molecular alterations that can be involved in BCRL pathogenesis and progression; (iii) to discuss the present and short-term future perspectives in biomarker-based patients' risk stratification; and (iv) to provide practical information that can be employed to improve the quality of life of these patients. |
format | Online Article Text |
id | pubmed-7142240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71422402020-04-16 Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema Invernizzi, Marco Lopez, Gianluca Michelotti, Anna Venetis, Konstantinos Sajjadi, Elham De Mattos-Arruda, Leticia Ghidini, Michele Runza, Letterio de Sire, Alessandro Boldorini, Renzo Fusco, Nicola Front Oncol Oncology Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast cancer survivors as a consequence of the axillary lymphatics' impairment after therapy (mainly axillary surgery and irradiation). Despite the recent achievements in the clinical management of these patients, BCRL is often diagnosed at its occurrence. In most cases, it remains a progressive and irreversible condition, with dramatic consequences in terms of quality of life and on sanitary costs. There are still no validated pre-surgical strategies to identify individuals that harbor an increased risk of BCRL. However, clinical, therapeutic, and tumor-specific traits are recurrent in these patients. Over the past few years, many studies have unraveled the complexity of the molecular and transcriptional events leading to the lymphatic system ontogenesis. Additionally, molecular insights are coming from the study of the germline alterations involved at variable levels in BCRL models. Regrettably, there is a substantial lack of predictive biomarkers for BCRL, given that our knowledge of its molecular milieu remains extremely puzzled. The purposes of this review were (i) to outline the biology underpinning the ontogenesis of the lymphatic system; (ii) to assess the current state of knowledge of the molecular alterations that can be involved in BCRL pathogenesis and progression; (iii) to discuss the present and short-term future perspectives in biomarker-based patients' risk stratification; and (iv) to provide practical information that can be employed to improve the quality of life of these patients. Frontiers Media S.A. 2020-04-02 /pmc/articles/PMC7142240/ /pubmed/32300557 http://dx.doi.org/10.3389/fonc.2020.00422 Text en Copyright © 2020 Invernizzi, Lopez, Michelotti, Venetis, Sajjadi, De Mattos-Arruda, Ghidini, Runza, de Sire, Boldorini and Fusco. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Invernizzi, Marco Lopez, Gianluca Michelotti, Anna Venetis, Konstantinos Sajjadi, Elham De Mattos-Arruda, Leticia Ghidini, Michele Runza, Letterio de Sire, Alessandro Boldorini, Renzo Fusco, Nicola Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
title | Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
title_full | Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
title_fullStr | Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
title_full_unstemmed | Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
title_short | Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
title_sort | integrating biological advances into the clinical management of breast cancer related lymphedema |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142240/ https://www.ncbi.nlm.nih.gov/pubmed/32300557 http://dx.doi.org/10.3389/fonc.2020.00422 |
work_keys_str_mv | AT invernizzimarco integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT lopezgianluca integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT michelottianna integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT venetiskonstantinos integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT sajjadielham integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT demattosarrudaleticia integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT ghidinimichele integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT runzaletterio integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT desirealessandro integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT boldorinirenzo integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema AT fusconicola integratingbiologicaladvancesintotheclinicalmanagementofbreastcancerrelatedlymphedema |